Polymyxin Resistance in Clinical Isolates of in Brazil: Update on Molecular Mechanisms, Clonal Dissemination and Relationship With KPC-Producing Strains
Overview
Infectious Diseases
Microbiology
Authors
Affiliations
In Brazil, the production of KPC-type carbapenemases in Enterobacteriales is endemic, leading to widespread use of polymyxins. In the present study, 502 isolates were evaluated for resistance to polymyxins, their genetic determinants and clonality, in addition to the presence of carbapenem resistance genes and evaluation of antimicrobial resistance. Resistance to colistin (polymyxin E) was evaluated through initial selection on EMB agar containing 4% colistin sulfate, followed by Minimal Inhibitory Concentration (MIC) determination by broth microdilution. The susceptibility to 17 antimicrobials was assessed by disk diffusion. The presence of , and carbapenemases was investigated by phenotypic methods and conventional PCR. Molecular typing was performed by PFGE and MLST. Allelic variants of the gene were screened by PCR and chromosomal mutations in the , , , and genes were investigated by sequencing. Our work showed a colistin resistance frequency of 29.5% (n = 148/502) in isolates. Colistin MICs from 4 to >128 µg/mL were identified (MIC = 64 µg/mL; MIC >128 µg/mL). All isolates were considered MDR, with the lowest resistance rates observed for amikacin (34.4%), and 19.6% of the isolates were resistant to all tested antimicrobials. The gene was identified in 77% of the isolates, in consonance with the high rate of resistance to polymyxins related to its use as a therapeutic alternative. Through -PFGE, 51 pulsotypes were identified. MLST showed 21 STs, with ST437, ST258 and ST11 (CC11) being the most prevalent, and two new STs were determined: ST4868 and ST4869. The gene was identified in 3 isolates. Missense mutations in chromosomal genes were identified, as well as insertion sequences in . Furthermore, the identification of chromosomal mutations in isolates belonging from CC11 ensures its success as a high-risk epidemic clone in Brazil and worldwide.
Attalla E, Khalil A, Zakaria A, Evans R, Tolba N, Mohamed N Gut Pathog. 2024; 16(1):73.
PMID: 39627871 PMC: 11616336. DOI: 10.1186/s13099-024-00667-z.
Fochat R, de Lelis Araujo A, Pereira Junior O, Silverio M, Figueiredo de Castro Nassar A, Junqueira M Braz J Microbiol. 2024; 55(4):3873-3884.
PMID: 39352656 PMC: 11711724. DOI: 10.1007/s42770-024-01531-7.
Lo C, Ritchie G, Bilawka J, Gowland L, Chorlton S, Jang W J Med Microbiol. 2024; 73(9).
PMID: 39222340 PMC: 11368154. DOI: 10.1099/jmm.0.001881.
Santos da Costa B, Peixoto R, da Conceicao Neto O, da Silva Pontes L, Tavares E Oliveira T, Tavares Teixeira C Braz J Microbiol. 2024; 55(4):3541-3550.
PMID: 39210190 PMC: 11712032. DOI: 10.1007/s42770-024-01464-1.
Koller B, Jania L, Li H, Barker W, Melander R, Melander C Antimicrob Agents Chemother. 2024; 68(10):e0067124.
PMID: 39194205 PMC: 11459950. DOI: 10.1128/aac.00671-24.